The shares of The Bank of New York Mellon Corporation (NYSE:BK) has been pegged with a rating of Neutral by Citigroup in its latest research note that was published on January 9th, 2019. Citigroup wasnâ€™t the only research firm that published a report of The Bank of New York Mellon Corporation, with other equities research analysts also giving their opinion on the stock. Keefe Bruyette advised investors in its research note published on October 19th, 2018, to Underperform the BK stock. The stock had earned Mkt Perform rating from Raymond James when it published its report on July 12th, 2018. The stock was given Neutral rating by Goldman in its report released on March 12th, 2018. BofA/Merrill was of a view that BK is Neutral in its latest report on March 7th, 2018. Morgan Stanley thinks that BK is worth Overweight rating. This was contained in the firmâ€™s report on January 19th, 2018.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 13 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $53.83. The price of the stock the last time has raised by 20.45% from its Week high price while it is raised higher than its 52-Week low price. A look at the stockâ€™s other technical shows that its 14-day RSI now stands at 58.95.
The shares of the company dipped by -0.40% during the trading session on Monday, reaching a low of $52.42 while ending the day at $52.60. During the trading session, a total of 4.58 million shares were traded which represents a 1.06% incline from the average session volume which is 4.63M shares. BK had ended its last session trading at 52.81. The Bank of New York Mellon Corporation currently has a market cap of $50.49B, while its P/E ratio stands at 13.38, while its P/E earnings growth sits at 7.85, with a beta of 1.02. The Bank of New York Mellon Corporation debt-to-equity ratio currently stands at 0.79, while its quick ratio hovers at . BK 52-week low price stands at $43.67 while its 52-week high price is $58.22.
The company in its last quarterly report recorded $0.99 earnings per share which is above the $0.92 predicted by most analysts. The The Bank of New York Mellon Corporation generated $4,007.00 million in revenue during the last quarter, which is slightly lower than the $4,024.50 million predicted by analysts. In the second quarter last year, the firm recorded $1.06 earnings per share. Compared to the same quarter last year, the firmâ€™s revenue was down by -7.07%. The Bank of New York Mellon Corporation has the potential to record 3.93 EPS for the current fiscal year, according to equities analysts.
Investment analysts at UBS published a research note on November 28th, 2018 where it informed investors and clients that Boston Scientific Corporation (NYSE:BSX) is now rated as Buy. Keefe Bruyette also rated BSX as Downgrade on October 19th, 2018, with its price target of $41 suggesting that BSX could surge by 14.11% from its current share price. Even though the stock has been trading at $37.73/share, analysts expect it to surge higher by 0.21% to reach $44.02/share. It started the day trading at $37.91 and traded between $37.49 and $37.81 throughout the trading session.
A look at its technical shows that BSXâ€™s 50-day SMA is 39.03 while its 200-day SMA stands at 36.50. The stock has a high of $41.00 for the year while the low is $27.91. The companyâ€™s P/E ratio currently sits at 33.02, while the P/B ratio is 6.00. At the moment, only of Boston Scientific Corporation shares were sold short. The companyâ€™s average trading volume currently stands at 7.02M shares, which means that the short-interest ratio is just 1.19 days. Over the past seven days, the company moved, with its shift of -0.89%. Looking further, the stock has raised 7.08% over the past 90 days while it gained 5.03% over the last six months.
The change in the stockâ€™s fortunes has led to several institutional investors altering their holdings of the stock. Fidelity Management Research Co sold more BSX shares, decreasing its portfolio by -8.06% during the last quarter. This move now sees Fidelity Management Research Co selling -12,906,910 shares in the last quarter, thus it now holds 147,177,590 shares of BSX, with a total valuation of $5,648,675,904. The Vanguard Group Inc meanwhile bought more BSX shares in the recently filed quarter, changing its stake to $3,910,697,285 worth of shares. Capital Research Management Co followed the path by increasing its BSX portfolio by +11.24% in the quarter. This means that Capital Research Management Co bought 10,101,411 shares in the last quarter and now controls 99,939,172 shares of the BSX stock, with the valuation hitting $3,835,665,421.
Similarly, Wellington Management Co LLP decreased its Boston Scientific Corporation shares by -0.24% during the recently filed quarter. After selling -153,985 shares in the last quarter, the firm now controls 63,232,247 shares of Boston Scientific Corporation which are valued at $2,426,853,640. In the same vein, SSgA Funds Management Inc increased its Boston Scientific Corporation shares by during the most recent reported quarter. The firm bought 2,869 shares during the quarter which increased its stakes to 56,679,322 shares and is now valued at $2,175,352,378. Following these latest developments, around 0.30% of Boston Scientific Corporation stocks are owned by institutional investors and hedge funds.